VendorsPeptide Sciences Is Gone: 5 Vendors Still Shipping
Most "alternatives" lists are ads. We compared 5 vendors on price, COA testing, and catalog depth — one scores 9.4/10 overall.
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
New articles delivered to your inbox every morning. Free.
4,721 daily price observations across 8 vendors and 69 peptides — median $/mg, volatility bands, and a 6.2% stockout rate. Trailing 90 days.
Simple Peptide publishes Freedom Diagnostics COAs, but Finnrick reports 28 of 47 lab tests passed. What we verified, what we couldn't, and alternatives.
Strate Labs is winding down July 1, 2026. We compared 5 vendors still shipping on price, COA testing, and catalog depth — one scores highest.
Lot-specific COAs, a 4.2 Trustpilot rating, and 15% off with our code. We checked the testing, pricing and catalog against every vendor we track.
Dated, sourced status table and readout log for every GLP-1, GIP, glucagon and amylin compound in trials or approved, with every estimand labelled.
Glacier Aminos is no longer on our recommended vendor list. What that means if you were planning to order, and the vendors we point buyers to now.
12 months of orders, 25+ peptides tested, every COA checked. 4.7★ rating, 10% code, fast shipping — real tracking data on quality and pricing.
Eternal Peptides closed September 15 and support ends Sept 30. We compared 6 vendors still shipping on price, COA testing, and catalog depth.
Chameleon Peptides closed after Visa questioned its card processing. What former customers need to save now, and 6 tracked vendors still shipping.
50% off sitewide tested across 6 months of real orders. Independent COA checks, BPC-157 at $25/10mg, shipping tracked. What the discount actually delivers.
Amino Asylum went offline in 2025 and never came back, and its old domain now points to Soma Chems. 3 vendors still shipping with third-party COA testing.
Lilly's eloraTZP reported 23.3% weight loss vs 14.8% on tirzepatide alone in type 2 diabetes, but up to 27% stopped treatment. What Phase 2b showed.
Survodutide hit 13.1% weight loss in type 2 diabetes at 76 weeks in NEJM, but 18% quit over GI effects. How it compares with tirzepatide and semaglutide.
Kailera's KAI-4729, a retatrutide-style triple agonist, posted 16% weight loss and a 67% liver-fat drop in 12 weeks at EASD. What's actually sourceable.
AbbVie's amylin analog ABBV-295 reported up to 9.8% weight loss in 12 weeks, and a half-life that could support monthly dosing. What EASD 2026 showed.
Novo paid $300M upfront for a weekly oral pill using tirzepatide's dual mechanism. What the $2.6B Hengrui deal signals, and what it changes for buyers.